Clinical Trials Browser

Phase 2 × Stomach Neoplasms × Capecitabine × Clear all

NCT04661150 2026-04-16

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Phase 2 Active not recruiting

42 enrolled 9 charts

Gastrointestinal

Stomach Neoplasms

NCT03161522 2026-04-15

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT07515625 2026-04-07

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2 Recruiting

GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05702229 2026-03-18

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06256328 2026-03-13

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT07069712 2026-03-10

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT07432295 2026-02-25

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Neoplasm Metastasis, Stomach Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Phase 2 Active not recruiting

40 enrolled 67 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT03257163 2026-01-20

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT06630130 2025-12-15

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT01191697 2025-11-03

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Phase 2 Completed

37 enrolled 11 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT04363801 2025-10-09

DisTinGuish

Phase 2 Terminated

247 enrolled 38 charts

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03929666 2025-09-12

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT07007182 2025-09-05

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02205047 2025-07-31

INNOVATION

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT03448835 2025-06-08

PANDA

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT06881017 2025-03-18

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT04034251 2025-02-03

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Phase 2 Completed

12 enrolled 18 charts

GastrointestinalGynecologic

Adenocarcinoma, Peritoneal Neoplasms, Stomach Neoplasms

NCT02485834 2025-01-20

FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

Phase 2 Terminated

5 enrolled 11 charts

Gastrointestinal

Stomach Neoplasms

NCT00780494 2025-01-14

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

Phase 2 Completed

35 enrolled 13 charts

GastrointestinalSarcoma

Stomach Neoplasms, Gastrointestinal Stromal Tumors

NCT06730373 2024-12-31

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06748508 2024-12-27

FDZL-GC003

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT04933227 2024-11-14

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Phase 2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT04937738 2024-11-06

PECORINO

Phase 2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT03469557 2024-10-23

BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Stomach Neoplasms

NCT06560528 2024-08-19

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06555471 2024-08-15

A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06451211 2024-06-11

Neo-ICEBOAT

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT02931890 2024-05-02

CRITICS-II

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT04908813 2024-04-15

Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT06310473 2024-03-15

Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT03950271 2024-02-28

SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT03472365 2024-01-11

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Phase 2 Completed

67 enrolled 12 charts

Gastrointestinal

Stomach Neoplasms

NCT05859477 2024-01-02

NIVOFGFR2

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT06155383 2023-12-14

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT05494060 2023-11-07

EXPLORING

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Stomach Neoplasms

NCT06094868 2023-10-23

Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT02555358 2023-10-19

Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT04250948 2023-08-01

Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT02954536 2023-03-16

Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

Phase 2 Completed

37 enrolled 8 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT05536102 2023-03-09

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT01665274 2022-10-03

repeat

Phase 2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT02335411 2022-08-08

KEYNOTE-059

Phase 2 Completed

318 enrolled 24 charts 2 FDA

Gastrointestinal

NCT01711242 2022-05-05

Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT04119622 2022-03-11

Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT05111444 2021-11-08

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT02128243 2021-03-26

MATEO

Phase 2 Completed

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms